Flu vaccine is worth the shot

The seasonal flu vaccine remains a central tool in public‑health strategy, despite periodic claims that it offers little protection. Recent data from the Centers for Disease Control and Prevention (CDC) and independent studies illustrate how the shot reduces illness, hospital visits, and deaths each year.

How effectiveness is measured

Each flu season features a different mix of influenza viruses, so manufacturers must predict which strains will dominate months before production begins. When the predicted strains align closely with those that circulate, vaccine effectiveness can rise above 60 percent; a poor match can drive it down to around 19 percent. The CDC reports an average effectiveness near 40 percent over recent seasons.

While that modest figure may seem modest, it reflects a meaningful reduction in risk across a large population. For example, the 2023‑2024 season saw the vaccine prevent an estimated 9.8 million flu‑related illnesses, 4.8 million medical visits, 120,000 hospitalizations, and 7,900 deaths. In one study, vaccinated individuals experienced a 31 percent lower risk of death compared with those who were not vaccinated.

Impact on children and vulnerable groups

Children benefit notably from vaccination. A 2022 study found that the flu shot lowered the risk of severe, life‑threatening influenza in children by 75 percent. Another analysis reported a 51 percent reduction in flu‑associated death among children with high‑risk conditions and a 65 percent drop among otherwise healthy youngsters.

Adults also see tangible gains. Effectiveness against hospitalization ranged from 52 percent to 61 percent for children and adolescents, and 41 percent to 44 percent for adults. Cutting the chance of a hospital stay roughly in half is a clear public‑health win.

For people who cannot receive the vaccine—such as those with certain medical contraindications—the broader community protection matters even more. Higher vaccination rates help limit virus spread, shielding those who remain unvaccinated.

From a practical standpoint, the vaccine’s benefits outweigh its risks. Aside from minor soreness or low‑grade fever, serious adverse events are rare. Anaphylaxis occurs in about one per 1.3 million doses, and Guillain‑Barré Syndrome (GBS) appears at a similar rate.

Vaccination saves lives.

Addressing misinformation

Critics sometimes cite anecdotal statements from individuals like Dr. Robert Malone, who has publicly called the flu shot “ineffective.” Such claims ignore the extensive epidemiological data that demonstrate measurable benefits. No single expert’s opinion can outweigh the collective findings of multiple studies and the ongoing surveillance conducted by public‑health agencies.

Health professionals, including epidemiologists and vaccine researchers, routinely receive the flu shot themselves and recommend it for their own families. Their confidence stems from a consistent record of preventing severe disease, not from any financial relationship with pharmaceutical companies.

In short, the evidence supports the seasonal flu vaccine as a valuable preventive measure. By lowering the incidence of illness, hospitalizations, and deaths, it serves both individual and community health interests.